financetom
Business
financetom
/
Business
/
Big hedge funds score gains with Trump election
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Big hedge funds score gains with Trump election
Dec 2, 2024 10:22 AM

By Carolina Mandl

NEW YORK, Dec 2 (Reuters) - A number of multi-billion

dollar hedge funds gained in November, numbers obtained by

Reuters show, riding the volatility of the U.S. presidential

election despite tight polling making positioning more difficult

for portfolio managers.

Following the election of Donald Trump on Nov. 5, U.S.

stocks, the dollar and bitcoin rallied, while the euro and the

Mexico's peso struggled. U.S. treasuries did well in November,

with the 10-year Treasury yield down by about 10 basis points

over the course of the month, as a rally at the end of the month

offset yield gains around the election.

Multi-strategy hedge funds Citadel and Schonfeld both gained

1.8% in their flagship funds Wellington and Strategic Partners

in November, according to sources. The Winton Fund gained 0.3%,

a separate source said.

Macro hedge fund Discovery Capital, founded by Rob Citrone,

jumped 14.5% last month, another person said. His fund is up

46.5% on the year.

Discovery, known as a "Tiger cub" as its founder worked for

legendary investor Julian Robertson at Tiger Management, Citrone

bets on macro trends as well as equities long and short

positions. All the asset classes were positive contributors to

performance, this source added.

See below hedge funds' performances in November:

Fund Performance in

November

Citadel 1.8%

Wellington

Citadel 1.6%

Tactical

Trading

Schonfeld 1.8%

Strategic

Partners

Schonfeld 1.6%

Fundamenta

l Equity

Discovery 14.5%

Capital

The Winton 0.3%

Fund

Winton 0.2%

Diversifie

d Macro

*Through Nov. 28th

(Reporting by Carolina Mandl, in New York; additional reporting

by Nell Mackenzie, in London, and Davide Barbuscia, in New York)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved